Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

British Journal of Dermatology

Volumn 171, Issue 6, 2014, Pages 1529-1532

  Brugiere C ^a,b   Stefan, A ^a   Morice, C ^a,b   Cornet, E ^a,b   Moreau, A ^a   Allouche, S ^a,b   Verneuil, L ^a,b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ABSORPTION SPECTROSCOPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ERYTHEMA; FEMALE; FILTER; HUMAN; MALE; METASTATIC MELANOMA; MIDDLE AGED; PHOTOSENSITIVITY; PHOTOTOXICITY; PROSPECTIVE STUDY; RADIOTHERAPY EQUIPMENT; SKIN TOXICITY; SPECTROPHOTOMETER; SPECTROPHOTOMETRY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; ULTRAVIOLET DETECTOR; ADVERSE EFFECTS; DERMATITIS, PHOTOTOXIC; MELANOMA; RADIATION RESPONSE; SKIN NEOPLASMS; ULTRAVIOLET RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DERMATITIS, PHOTOTOXIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; ERYTHEMA; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; ULTRAVIOLET RAYS;

EID: 84919458944     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13300     Document Type: Article

References (10)

1. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Flaherty KT, Puzanov I, Kim KB, et al,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
3. Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
4. Dummer R, Rinderknecht J, Goldinger SM,. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366: 480-1.
5. Manousaridis I, Mavridou S, Goerdt S, et al,. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol 2013; 27: 11-18.
6. Mattei PL, Alora-Palli MB, Kraft S, et al,. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-7.
7. Boussemart L, Routier E, Mateus C, et al,. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691-7.
8. Lacouture ME, Duvic M, Hauschild A, et al,. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
9. Gelot P, Dutartre H, Khammari A, et al,. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol 2013; 22: 297-8.
10. Holzle E, Plewig G, Lehmann P,. Photodermatoses-diagnostic procedures and their interpretation. Photodermatology 1987; 4: 109-14.